JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $79

Benzinga · 3d ago
JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $78 to $79.